We are live on ! Find out more

2,059 hedge funds and large institutions have $140B invested in Pfizer in 2016 Q4 according to their latest regulatory filings, with 193 funds opening new positions, 870 increasing their positions, 797 reducing their positions, and 64 closing their positions.

New
Increased
Maintained
Reduced
Closed

202% more first-time investments, than exits

New positions opened: 193 | Existing positions closed: 64

5% more funds holding

Funds holding: 1,9622,059 (+97)

9% more repeat investments, than reductions

Existing positions increased: 870 | Existing positions reduced: 797

0.04% more ownership

Funds ownership: 74.71%74.74% (+0.04%)

3% less capital invested

Capital invested by funds: $144B → $140B (-$4.35B)

17% less call options, than puts

Call options by funds: $2.07B | Put options by funds: $2.49B

26% less funds holding in top 10

Funds holding in top 10: 234172 (-62)

Holders
2,059
Holders Change
+97
Holders Change %
+4.94%
% of All Funds
51.48%
Holding in Top 10
172
Holding in Top 10 Change
-62
Holding in Top 10 Change %
-26.5%
% of All Funds
4.3%
New
193
Increased
870
Reduced
797
Closed
64
Calls
$2.07B
Puts
$2.49B
Net Calls
-$424M
Net Calls Change
-$342M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$13.1B +$283M +9,285,790 +2%
State Street
2
State Street
Massachusetts
$10.4B +$349M +11,423,740 +3%
BIT
3
BlackRock Institutional Trust
California
$5.44B +$105M +3,447,878 +2%
Bank of America
4
Bank of America
North Carolina
$3.82B +$131M +4,298,874 +4%
JP Morgan Chase
5
JP Morgan Chase
New York
$3.64B -$87.9M -2,879,958 -2%
BFA
6
BlackRock Fund Advisors
California
$3.42B +$238M +7,806,087 +8%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$2.63B -$400M -13,086,713 -13%
Northern Trust
8
Northern Trust
Illinois
$2.61B -$62.8M -2,058,035 -2%
Bank of New York Mellon
9
Bank of New York Mellon
New York
$2.35B -$209M -6,849,771 -8%
Wellington Management Group
10
Wellington Management Group
Massachusetts
$2.23B -$110M -3,594,871 -5%
BG
11
BlackRock Group
United Kingdom
$2.11B +$201M +6,573,236 +11%
Ameriprise
12
Ameriprise
Minnesota
$2.04B -$89.6M -2,934,131 -4%
State Farm Mutual Automobile Insurance
13
State Farm Mutual Automobile Insurance
Illinois
$1.94B
Norges Bank
14
Norges Bank
Norway
$1.9B +$55.6M +1,819,760 +3%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.82B +$85.7M +2,807,784 +5%
BA
16
BlackRock Advisors
Delaware
$1.8B +$251M +8,209,319 +16%
Massachusetts Financial Services
17
Massachusetts Financial Services
Massachusetts
$1.53B -$99.1M -3,246,631 -6%
Morgan Stanley
18
Morgan Stanley
New York
$1.48B +$202M +6,600,985 +16%
Barrow, Hanley, Mewhinney & Strauss
19
Barrow, Hanley, Mewhinney & Strauss
Texas
$1.47B -$60M -1,965,818 -4%
Invesco
20
Invesco
Georgia
$1.43B -$36.5M -1,194,646 -3%
Franklin Resources
21
Franklin Resources
California
$1.42B -$13.8M -453,180 -1%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$1.3B -$16.7M -546,192 -1%
Deutsche Bank
23
Deutsche Bank
Germany
$1.26B -$155M -5,062,494 -11%
AllianceBernstein
24
AllianceBernstein
Tennessee
$1.24B -$76.1M -2,491,590 -6%
Goldman Sachs
25
Goldman Sachs
New York
$1.23B +$150M +4,916,600 +14%

PFE Hedge Fund Activity: Q4 2016 in Review

2,059 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2016, worth a combined $140B — down 3% from $144B a quarter earlier.

Buyers outnumbered sellers: 193 funds opened new PFE positions and 64 closed out — a net gain of 129 holders — while 870 added to existing stakes and 797 trimmed.

The largest buyer was Boston Partners, adding an estimated $550M. The largest seller was Capital World Investors, cutting an estimated $1.63B.

  • 2,059 institutional investors held Pfizer (PFE) as of Q4 2016, up from 1,962 in Q3 2016.
  • Funds reported $140B of Pfizer stock for Q4 2016, down 3% quarter-over-quarter.
  • 193 funds opened new Pfizer positions in Q4 2016 and 64 closed out, a net change of +129 holders.
  • The largest Pfizer buyer in Q4 2016 was Boston Partners, an estimated $550M added.
  • The largest Pfizer seller in Q4 2016 was Capital World Investors, an estimated $1.63B sold.

Based on aggregated 13F filings for Q4 2016.